BioXcel Therapeutics, Inc. (BTAI) announced Loss for fourth quarter of -$10.86 million
The company's bottom line came in at -$10.86 million, or -$3.57 per share. This compares with -$22.26 million, or -$12.09 per share, last year.
The company's revenue for the period fell 2.6% to $0.37 million from $0.38 million last year.
BioXcel Therapeutics, Inc. earnings at a glance (GAAP) :
-Earnings: -$10.86 Mln. vs. -$22.26 Mln. last year.-EPS: -$3.57 vs. -$12.09 last year.-Revenue: $0.37 Mln vs. $0.38 Mln last year.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.